Learn More
8543 We found that repeated rituximab exposure leads to deregulation of Bcl-2 proteins and concomitant chemotherapy resistance. We demonstrated that obatoclax (O), a potent Bcl-2 inhibitor, enhanced(More)
Age in years (median, range) 45 (10-46) 32(13-56) .83 Conditioning regimen Myeloablative 4/5 (80%) 8/10 (80%) 1.0 Reduced intensity 1/5 (20%) 2/10 (20%) 1.0 aGVHD 1/5 (20%) 7/10 (70%) .12 Grade II-IV(More)
  • 1